| Name | Title | Contact Details |
|---|---|---|
Denise Fredericksen |
Area Sales Director | Profile |
Jennifer Vidal-Gianni |
Chief Human Resources Officer | Profile |
Jennifer Mullarkey |
VP Fragrance and Product Development | Profile |
Baerbel Bureick |
Chief Marketing Officer & Chief Marketing Officer | Profile |
Paramus Surgical Ctr is a Paramus, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stellar Health is a healthcare technology company that helps providers and health insurance companies improve quality and financial performance by prompting providers and their practice staff with recommended value-based actions and real-time payments at the point of care. The Stellar platform is a proprietary web-based tool that delivers targeted recommendations designed to meet the new objectives of value-based care delivery models. Stellar Health maintains a culture of compassion, both internally and externally. Their mission is to learn, grow, succeed, and always enjoy the ride.
WellCare Health Plans (NYSE: WCG) is a FORTUNE 500 company based in Tampa, Fla., employing more than 5,000 associates nationwide. WellCare has developed a full complement of expertise in the three major areas of government-sponsored health care…. Medicaid, Medicare Advantage and Medicare Prescription Drug Plans. Leveraging these for our members` benefit is a key part of the value we bring to our members. WellCare has a focus on those members who are dually eligible for both Medicaid and Medicare. This is an area of specialization that many other health plans simply do not have. We are committed to continually improving the quality of care and service that we provide to our members. We help our members access the right care at the right time in the appropriate setting through coordinated care teams and community partnerships. And we`re focused on government customers and use a disciplined approach to ensuring a competitive cost structure.
IMAC Regeneration Centers offers long-term solutions for chronic musculoskeletal conditions without surgery or opioids. This state-of-the-art medical treatment utilizes a combination of regenerative medicine and rehabilitation to prevent the most common unnecessary surgeries, including spinal fusion and laminectomy, and knee and hip replacements. Each of these surgeries require an opioid prescription 99.9% of the time, leading to a high risk of addiction and never returning to work.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.